Lupin has entered into a research and development pact with Medicis Pharmaceutical Corporation to apply proprietary Lupin formulation technologies to multiple therapeutic compounds.
Under the terms of the agreement, Lupin will receive a $20 million upfront payment from Medicis and will be primarily responsible for formulating certain novel therapeutic products for Medicis, utilizing several of Lupin’s formulation technologies.
Lupin an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The company today has significant presence in Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infective and NSAIDs in addition to holding global leadership positions in the Anti-TB and Cephalosporins space.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1454.45 |
Dr. Reddys Lab | 5789.90 |
Cipla | 1451.80 |
Zydus Lifesciences | 1033.00 |
Lupin | 1584.60 |
View more.. |